Close Menu

NEW YORK – Thermo Fisher Scientific said on Tuesday that it has expanded its strategic partnership with Agios Pharmaceuticals to codevelop a companion diagnostic test to identify low-grade glioma patients with IDH1 and IDH2 mutations who may be eligible for Agios' investigational inhibitor vorasidenib.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.